ライゾデグの薬剤に関する洞察と市場予測：2032年

ライゾデグ70/30（インスリンデグルデク、インスリンアスパルト）は、長時間作用型インスリンアナログと速効型ヒトインスリンアナログの配合剤で、成人糖尿病患者の血糖コントロール改善を適応とします。

ライゾデグの開始用量は、1日に必要なインスリン量の60～70％が推奨されています。本剤は1日1回食事時に使用し、残りの食事時には短時間/速効型インスリン製剤を併用し、その後、個別に用量を調節します。

インスリンデグルデクおよびインスリンアスパルトは、ヒトインスリンレセプターに特異的に結合し、ヒトインスリンと同様の薬理作用を示します。インスリンの血糖降下作用は、筋肉や脂肪細胞上の受容体にインスリンが結合することでグルコースの取り込みが促進され、同時に肝臓からのグルコース産生が抑制されることによるものです。

今後数年間で、1型糖尿病の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ライゾデグの優位性に影響を与える可能性のある機会を模索しています。1型糖尿病に対する他の新興製品もライゾデグと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要6ヶ国におけるライゾデグ市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 1型糖尿病に対するライゾデグの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ライゾデグ市場評価

• 1型糖尿病に対するライゾデグの市場展望
• 主要6ヶ国市場分析
  • 主要6ヶ国における1型糖尿病に対するライゾデグの市場規模
• 国別市場分析
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: RYZODEG, Clinical Trial Description, 2023
• Table 2: RYZODEG, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: RYZODEG Market Size in the 6MM, in USD million (2019-2032)
• Table 6: RYZODEG Market Size in Germany, in USD million (2019-2032)
• Table 7: RYZODEG Market Size in France, in USD million (2019-2032)
• Table 8: RYZODEG Market Size in Italy, in USD million (2019-2032)
• Table 9: RYZODEG Market Size in Spain, in USD million (2019-2032)
• Table 10: RYZODEG Market Size in the UK, in USD million (2019-2032)
• Table 11: RYZODEG Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: RYZODEG Market Size in the 6MM, USD million (2019-2032)
• Figure 2: RYZODEG Market Size in Germany, USD million (2019-2032)
• Figure 3: RYZODEG Market Size in France, USD million (2019-2032)
• Figure 4: RYZODEG Market Size in Italy, USD million (2019-2032)
• Figure 5: RYZODEG Market Size in Spain, USD million (2019-2032)
• Figure 6: RYZODEG Market Size in the United Kingdom, USD million (2019-2032)
• Figure 7: RYZODEG Market Size in Japan, USD million (2019-2032)

“"RYZODEG Drug Insight and Market Forecast - 2032" report provides comprehensive insights about RYZODEG for type 1 diabetes mellitus in the six major markets. A detailed picture of the RYZODEG for type 1 diabetes mellitus in the 6MM, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the RYZODEG for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RYZODEG market forecast analysis for type 1 diabetes mellitus in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary:

RYZODEG 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog, and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus.

The recommended starting dose of RYZODEG is 60-70% of the total daily insulin requirements. This medicinal product is used once daily at mealtime, combined with short-/rapid-acting insulin at the remaining meals, followed by individual dosage adjustments.

Insulin degludec and insulin aspart bind specifically to the human insulin receptor, resulting in the same pharmacological effects as human insulin. The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and the simultaneous inhibition of glucose output from the liver.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the RYZODEG description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
• Elaborated details on RYZODEG regulatory milestones and other development activities have been provided in this report.
• The report also highlights the RYZODEG research and development activities in type 1 diabetes mellitus across the Europe and Japan.
• The report also covers the patents information with expiry timeline around RYZODEG.
• The report contains forecasted sales of RYZODEG for type 1 diabetes mellitus till 2032.
• Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
• The report also features the SWOT analysis with analyst views for RYZODEG in type 1 diabetes mellitus.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RYZODEG Analytical Perspective by DelveInsight

In-depth RYZODEG Market Assessment

This report provides a detailed market assessment of RYZODEG for type 1 diabetes mellitus in the six major markets, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

RYZODEG Clinical Assessment

The report provides the clinical trials information of RYZODEG for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RYZODEG dominance.
• Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to RYZODEG and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RYZODEG in type 1 diabetes mellitus.
• Our in-depth analysis of the forecasted sales data of RYZODEG from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RYZODEG in type 1 diabetes mellitus.

Key Questions:

• What is the product type, route of administration and mechanism of action of RYZODEG?
• What is the clinical trial status of the study related to RYZODEG in type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RYZODEG development?
• What are the key designations that have been granted to RYZODEG for type 1 diabetes mellitus?
• What is the forecasted market scenario of RYZODEG for type 1 diabetes mellitus?
• What are the forecasted sales of RYZODEG in the six major countries, including Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to RYZODEG for type 1 diabetes mellitus?
• Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?

Table of Contents

1. Report Introduction

2. RYZODEG Overview in type 1 diabetes mellitus

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. RYZODEG Market Assessment

• 5.1. Market Outlook of RYZODEG in type 1 diabetes mellitus
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of RYZODEG in the 6MM for type 1 diabetes mellitus
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of RYZODEG in Germany for type 1 diabetes mellitus
  • 5.3.2. Market Size of RYZODEG in France for type 1 diabetes mellitus
  • 5.3.3. Market Size of RYZODEG in Italy for type 1 diabetes mellitus
  • 5.3.4. Market Size of RYZODEG in Spain for type 1 diabetes mellitus
  • 5.3.5. Market Size of RYZODEG in the United Kingdom for type 1 diabetes mellitus
  • 5.3.6. Market Size of RYZODEG in Japan for type 1 diabetes mellitus

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options